GW suffers major blow as US sinks bid to patent cannabinoids for epilepsy

British firm GW Pharmaceuticals is licking its wounds after US judges tossed out its attempt to patent multiple cannabinoids for epilepsy treatment following an eight-year battle. The US Patent Trial and Appeal Board, an administrative law body of the national patent office, denied patent US9066920B2 on January 3, siding with petitioner Insys, a rival biotech firm.

Continue Reading →

Here’s Why The FDA Approval Of Epidiolex Is Significant, According To Dr. Green

The FDA has made a big step forward with the approval of Epidiolex, the first approved medication derived directly from the cannabis plant.

The post Here’s Why The FDA Approval Of Epidiolex Is Significant, According To Dr. Green appeared first on The Fresh Toast.

Continue Reading →